PrEP

09_prep_shutterstock.jpg

A recommendation that the HIV prevention drug PrEP be approved for public subsidy has been hailed as an essential step in Australia's response to HIV.

23_prep_shutterstock.jpg

The Kirby Institute has been a key player in NSW’s partnership response to HIV, which has reached a historic milestone. 

14_gay_relationship_shutterstock.jpg

UNSW researcher Martin Holt will explore the social impacts of rapid changes in HIV prevention when he delivers a free public lecture on 22 February.

PrEP

The Kirby Institute at UNSW has welcomed the Therapeutic Goods Administration's approval of antiretroviral drug Truvada as pre-exposure prophylaxis (PrEP) in Australia.

01_prep_pill.jpg

A landmark clinical trial led by UNSW researchers aims to halve new HIV infections in NSW within two years and 'virtually eliminate' HIV transmission by 2020.

HIVNegative 119653054 1

The Kirby Insitute at UNSW has launched a feasibility study to examine whether HIV negative people can take combination drug therapy to reduce their risk of acquiring the virus.